Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33248018.
- Also identified by DOI 10.1016/j.cmet.2020.11.015 and PMC identifier 7685630.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes.
Medical subject headings
- COVID-19
- Diabetes Mellitus, Type 2
- Glucose
- Insulins
- SARS-CoV-2